GSA Capital Partners LLP Sells 230,470 Shares of FibroGen, Inc. (NASDAQ:FGEN)

GSA Capital Partners LLP reduced its position in shares of FibroGen, Inc. (NASDAQ:FGEN) by 17.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,095,866 shares of the biopharmaceutical company’s stock after selling 230,470 shares during the quarter. GSA Capital Partners LLP owned 1.09% of FibroGen worth $438,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Cubist Systematic Strategies LLC raised its position in FibroGen by 3,906.9% during the second quarter. Cubist Systematic Strategies LLC now owns 287,332 shares of the biopharmaceutical company’s stock worth $256,000 after acquiring an additional 280,161 shares in the last quarter. Point72 DIFC Ltd increased its holdings in shares of FibroGen by 734.2% in the second quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 45,990 shares during the last quarter. XTX Topco Ltd acquired a new position in shares of FibroGen in the second quarter valued at $424,000. Acadian Asset Management LLC increased its holdings in shares of FibroGen by 34.4% in the second quarter. Acadian Asset Management LLC now owns 3,364,719 shares of the biopharmaceutical company’s stock valued at $2,997,000 after purchasing an additional 860,854 shares during the last quarter. Finally, Sei Investments Co. increased its holdings in shares of FibroGen by 38.4% in the second quarter. Sei Investments Co. now owns 149,342 shares of the biopharmaceutical company’s stock valued at $133,000 after purchasing an additional 41,442 shares during the last quarter. 72.71% of the stock is owned by institutional investors.

Analysts Set New Price Targets

FGEN has been the topic of several research reports. StockNews.com initiated coverage on shares of FibroGen in a research note on Thursday, November 14th. They issued a “hold” rating on the stock. William Blair restated a “market perform” rating on shares of FibroGen in a research note on Wednesday, November 13th.

FibroGen Stock Performance

FGEN stock opened at $0.35 on Thursday. The stock has a market capitalization of $35.27 million, a P/E ratio of -0.28 and a beta of 0.72. FibroGen, Inc. has a 12 month low of $0.18 and a 12 month high of $2.93. The firm has a 50-day moving average price of $0.36 and a 200-day moving average price of $0.70.

FibroGen (NASDAQ:FGEN) last issued its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.21. The business had revenue of $46.33 million during the quarter, compared to the consensus estimate of $34.00 million. During the same quarter last year, the business earned ($0.52) EPS. As a group, equities analysts predict that FibroGen, Inc. will post -0.86 EPS for the current fiscal year.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.